---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-003639"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:03:13.304617+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Roivant Q3 loss $208.9M; cash $5.2B; launches brepocitinib Ph2 in sarcoidosis

## Summary
- Revenue $9.0M (-42% YoY); loss from continuing ops $208.9M vs. $5.1B income in prior year (Telavant gain).
- Cash and marketable securities $5.2B at Dec 31; plus $75M VTAMA milestone and $113M from Immunovant private placement.
- New brepocitinib Phase 2 in cutaneous sarcoidosis; topline data expected H2 2026.
- Batoclimab pivotal trial results in MG and CIDP expected by March 31, 2025; IMVT-1402 pivotal trials initiated in GD and D2T RA.
- LNP litigation vs. Moderna: summary judgment Q2/Q3 2025, jury trial Sept 2025.

## SEC filing metadata
- accession: 0001140361-25-003639
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036125003639/0001140361-25-003639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036125003639/ef20043151_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-003639
- JSON: https://secwatch.observer/filing/0001140361-25-003639.json
- Plain text: https://secwatch.observer/filing/0001140361-25-003639.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.